|
- Use only analytically and clinically validated
HPV tests.
- Test for high-risk HPV types only. There is
no role for low-risk-HPV testing in a cervical cancer screening program.
- Screening can use co-testing with Pap and
HPV in women over 30 years. If both tests are negative, re-screen in
three years.
- HPV testing of adolescents is unacceptable.
- Reflex HPV testing for the triage of women
with ASC-US is preferred, except in women 20 years of age or younger.
- Reflex HPV testing for the triage of postmenopausal
women with LSIL is an acceptable choice.
- HPV testing may be used as a stand-alone
test in the post-colposcopy and post-treatment management guidelines.
- Use HPV testing in the post-colposcopy management
of low-grade abnormalities at 12-month intervals.
- Use HPV testing in the post-treatment management
of HSIL and AIS at six- to 12-month intervals as test of cure.
Dr. Darragh, a member
of the CAP Cytopathology Committee, is professor of clinical pathology,
Departments of Pathology and Ob/Gyn, University of California San Francisco/Mt.
Zion Medical Center, San Francisco. Dr. Colgan, a former member of the Cytopathology
Committee, is chief, gynecologic pathology, Department of Pathology and
Laboratory Medicine, Mount Sinai Hospital, Toronto, and professor, University
of Toronto. |
|
|
Related Links
